Valuation dashboard for Protagonist Therapeutics, Inc. (PTGX) with P/E 140.13, P/B 11.35, EV/EBITDA 104.4 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Analysis Summary
Protagonist Therapeutics, Inc. reported revenue of $46.0M in the most recent fiscal year, growing at a 5-year CAGR of 10.0%.
Trailing-twelve-month margins: gross margin 99.9%, operating margin 20.7%, net margin 29.4%.
At $144.85 (closing price, October 30, 2026), PTGX trades at a P/E of 140.13 and an ROE of 12.03%. Market capitalisation stands at $9.4B.
Balance sheet quality for PTGX: debt-to-equity ratio of 0.01, current ratio of 21.71 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 140.13 |
| Price / Book | 11.35 |
| EV / EBITDA | 104.4 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | $9.4B | 140.13 | 11.35 | 12.0% |
| IMVT | Immunovant, Inc. | $6.0B | 8.15 | -69.6% | |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 7.43 | -24.3% | |
| IRON | Disc Medicine, Inc. | $3.1B | 4.85 | -37.2% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $141.7B | 32.53 | 7.01 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% |
Price
| Price | $144.85 (closing price, October 30, 2026) |
| Market Cap | $9.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 12.03% |
| Return on Invested Capital | 6.74% |
| Return on Assets | 9.36% |
| Gross Margin | 99.86% |
| Operating Margin | 20.69% |
| Net Margin | 29.40% |
Related companies: IMVT · SYRE · IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks